[1]
Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332(15): 1004-14.
[2]
Vaishampayan U, Parchment RE, Jasti BR, Hussain M. Taxanes: An overview of the pharmacokinetics and pharmacodynamics. Urology 1999; 54: 22-9.
[3]
Crown J, O’Leary M. The taxanes: An update. Lancet 2000; 355: 1176-8.
[4]
Crown J, O’Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: A review of clinical experience. Oncologist 2004; 9(2): 24-32.
[5]
Sacco PC, Gridelli C. An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma. Expert Opin Emerg Drugs 2017; 22(3): 213-22.
[6]
Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz JA. Docetaxel in prostate cancer: A familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol 2017; 9: 307-18.
[7]
Haltia UM, Andersson N, Yadav B, et al. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells. Gynecol Oncol 2017; 144(3): 621-30.
[8]
Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Seminars Opthalmology 2007; 22: 151-3.
[9]
Tan WW, Walsh T. Ocular toxicity secondary to paclitaxel in two lung cancer patients. Med Pediatr Oncol 1998; 31: 177.
[10]
Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf 2008; 31: 127-41.
[11]
Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-803.
[12]
Georgakopoulos CD, Makri OE, Vasilakis P, Exarchou A. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom 2012; 95: 233-6.
[13]
Koo NK, Kim YC. A case of paclitaxel-induced maculopathy treated with methazolamide. Korean J Ophthalmol 2012; 26: 394-7.
[14]
Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 2003; 80: 277-9.
[15]
Nakao S, Ikeda Y, Emi Y, Ishibashi T. Possibility of muller cell dysfunction as the pathogenesis of paclitaxel maculopathy. Ophthalmic Surg Lasers Imaging Retina 2016; 47: 81-4.
[16]
Tezcan Y, Surmeli M, Tastekin D, Koc M. Bilateral cystoid macular edema secondary to paclitaxel treatment. Arch Iran Med 2015; 18: 606-7.
[17]
Freitas-da-Costa P, Brandao E, Braganca T, Falcao-Reis F, Carneiro A. Multimodal imaging in paclitaxel-induced macular edema: The microtubule disfunction. Cutan Ocul Toxicol 2015; 34: 347-9.
[18]
Haider A, Bababeygy SR, Lu SY. Cystoid macular edema and macular pigmentation associated with nab-Paclitaxel therapy. Retin Cases Brief Rep 2015; 9: 220-2.
[19]
Kuznetcova TI, Cech P, Herbort CP. The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol 2012; 32: 299-304.
[20]
Matsuoka N, Hasebe H, Mayama T, Fukuchi T. Sub-Tenon injections of triamcinolone acetonide had limited effect on cystoid macular edema secondary to nanoparticle albumin-bound-paclitaxel (abraxane). Case Rep Ophthalmol Med 2015; 2015: 181269.
[21]
Rahimy E, Sarraf D. Cystoid macular edema secondary to nanoparticle albumin-bound Paclitaxel therapy. Ophthalmic Surg Lasers Imaging Retina 2013; 44: 187-9.
[22]
Baskin DE, Garg SJ. Abraxane-induced cystoid macular edema refractory to concomitant intravenous bevacizumab. Can J Ophthalmol 2011; 46: 200-1.
[23]
Ham DS, Lee JE, Kim HW, Yun IH. A case of cystoid macular edema associated with Paclitaxel chemotherapy. Korean J Ophthalmol 2012; 26: 388-90.
[24]
Rahman HT, Yeh S, Bergstrom CS. Cystoid macular edema without leakage secondary to nab-Paclitaxel (Abraxane): Clinical experience with intravitreal bevacizumab. J Ocul Pharmacol Ther 2013; 29: 360-2.
[25]
Dwivedi R, Tiroumal S. Possible efficacy of topical dorzolamide in the treatment of paclitaxel-related cystoid macular edema. Retin Cases Brief Rep 2018; 12(1): 75-9.
[26]
Ehlers JP, Rayess H, Steinle N. Topical dorzolamide therapy for taxane-related macular oedema. Eye (London, England) 2013; 27: 102-4.
[27]
Hassall MM, Andrew NH. Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema. BMJ Case Rep 2016; 2016: 10.
[28]
Meyer KM, Klink T, Ugurel S, Brocker EB. Regression of paclitaxel-induced maculopathy with oral acetazolamide. Graefes Arch Clin Exp Ophthalmol 2012; 250: 463-4.
[29]
Murphy CG, Walsh JB, Hudis CA, Lake D, Theodoulou M. Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol 2010; 28: e684-7.
[30]
Modi D, Dubovy SR. Non-leaking cystoid maculopathy secondary to systemic paclitaxel. Ophthalmic Surg Lasers Imaging Retina 2013; 44: 183-6.
[31]
Padron Perez N, Rubio Caso MJ, Arias Barquet L, Caminal Mitjana JM. Bilateral cystoid macular edema in a patient with taxane-based chemotherapy. Can J Ophthalmol 2013; 48: e3-4.
[32]
Park E, Goldberg NR, Adams S. Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy. Anticancer Drugs 2016; 27: 580-4.
[33]
Risard SM, Pieramici DJ, Rabena MD. Cystoid macular edema secondary to Paclitaxel (abraxane). Retin Cases Brief Rep 2009; 3: 383-5.
[34]
Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 2008; 126: 1605-6.
[35]
Tanaka Y, Bando H, Hara H, Ito Y, Okamoto Y. Cystoid macular edema induced by nab-paclitaxel. Breast Cancer 2015; 22: 324-6.
[36]
Chelala E, Arej N, Antoun J, et al. Central macular thickness monitoring after a taxane-based therapy in visually asymptomatic patients. Chemotherapy 2017; 62: 199-204.
[37]
Schneider CA, Rasband WS, Eliceiri KW. NIH image to imageJ: 25 years of image analysis. Nat Methods 2012; 9: 671-5.
[38]
Kanakis MG, Giannouli K, Andreanos K, et al. Capillary nonperfusion and photoreceptor loss in branch retinal vein occlusion: Spatial correlation and morphologic characteristics. Retina 2017; 37: 1710-22.
[39]
Antcliff RJ, Hussain AA, Marshall J. Hydraulic conductivity of fixed retinal tissue after sequential excimer laser ablation: Barriers limiting fluid distribution and implications for cystoid macular edema. Arch Ophthalmol 2001; 119: 539-44.
[40]
Bringmann A, Reichenbach A, Wiedemann P. Pathomechanisms of cystoid macular edema. Ophthalmic Res 2004; 36: 241-9.
[41]
Tso MO. Pathological study of cystoid macular oedema. Transactions of the ophthalmological societies of the United Kingdom. Trans Ophthalmol Soc U K 1980; 100: 408-13.
[42]
Bringmann A, Pannicke T, Grosche J, et al. Muller cells in the healthy and diseased retina. Prog Retin Eye Res 2006; 25: 397-424.
[43]
Joshi MM, Garretson BR. Paclitaxel maculopathy. Arch Ophthalmol 2007; 125: 709-10.
[44]
Rao RC, Choudhry N. Cystoid macular edema associated with chemotherapy. CMAJ 2016; 188: 216.
[45]
Sridhar J, Shahlaee A, Ehmann D, et al. En face optical coherence tomography and optical coherence tomography angiography imaging of taxane-associated cystoid macular edema. Ophthalmic Surg Lasers Imaging Retina 2016; 47: 176-9.
[46]
Spaide RF. Retinal vascular cystoid macular edema: Review and new theory. Retina 2016; 36: 1823-42.
[47]
Verkman AS. Aquaporin water channels and endothelial cell function. J Anat 2002; 200: 617-27.
[48]
Mazzaferri J, Costantino S, Lefrancois S. Analysis of AQP4 trafficking vesicle dynamics using a high-content approach. Biophys J 2013; 105: 328-37.
[49]
Musch A. Microtubule organization and function in epithelial cells. Traffic 2004; 5: 1-9.
[50]
Petrovic MM, Vales K, Stojan G, Basta-Jovanovic G, Mitrovic DM. Regulation of selectivity and translocation of aquaporins: An update. Folia Biol (Praha) 2006; 52: 173-80.
[51]
Conner MT, Conner AC, Brown JE, Bill RM. Membrane trafficking of aquaporin 1 is mediated by protein kinase C via microtubules and regulated by tonicity. Biochemistry 2010; 49: 821-3.
[52]
Nedvetsky PI, Tamma G, Beulshausen S, Valenti G, Rosenthal W, Klussmann E. Regulation of aquaporin-2 trafficking. Handb Exp Pharmacol 2009; 190: 133-57.
[53]
Brown D. Targeting of membrane transporters in renal epithelia: When cell biology meets physiology. Am J Physiol Renal Physiol 2000; 278: F192-201.
[54]
Sparrrow JR, Hicks D, Hamel CP. The retinal pigment epithelium in health and disease. Curr Mol Med 2010; 10: 802-23.
[55]
Stamer WD, Bok D, Hu J, Jaffe GJ, McKay BS. Aquaporin-1 channels in human retinal pigment epithelium: Role in transepithelial water movement. Invest Ophthalmol Vis Sci 2003; 44: 2803-8.
59
3
2
1